VirbacLTS:0NM7 -1.53%91 FCF Margin % is 16.94% as of Dec. 2025, which is 114% above its 10-year median of 7.93. GuruFocus rates LTS:0NM7 with a GF Score™ of 91/100 and a GF Value™ of €364.75 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 962 Drug Manufacturers companies, Virbac ranks better than 61.54% on this metric.
FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Virbac's Free Cash Flow for the
six
months ended in Dec. 2025 was €123 Mil. Virbac's Revenue for the
six
months ended in Dec. 2025 was €726 Mil. Therefore, Virbac's FCF Margin % for the quarter that ended in Dec. 2025 was 16.94%.
The historical rank and industry rank for Virbac's FCF Margin % or its related term are showing as below:
LTS:0NM7'
s FCF Margin % Range Over the Past 10 Years
Min: 3.73 Med: 7.93 Max: 11.75
Current: 6.61
During the past 13 years, the highest FCF Margin % of Virbac was 11.75%. The lowest was 3.73%. And the median was 7.93%.
LTS:0NM7's FCF Margin % is ranked better than 61.54% of 962
companies
in the Drug Manufacturers industry
Industry Median: 2.51
vs LTS:0NM7: 6.61
Virbac FCF Margin % Related Terms
Virbac FCF Margin % Historical Data
* Premium members only.
The historical data trend for Virbac's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0NM7 vs LLY, JNJ, ABBV: FCF Margin % Comparison
For the Drug Manufacturers - General subindustry, Virbac's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Virbac FCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Virbac's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Virbac's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Virbac (LTS:0NM7) has a FCF Margin % of 16.94% as of Dec. 2025. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Virbac and its competitors. This is 114% above median its historical median of 7.93. Over the past decade, Virbac's FCF Margin % has ranged from 3.73 to 11.75. According to the industry distribution chart, Virbac ranks #370 out of 962 companies in the Drug Manufacturers industry, placing it in the top 38.5%.
Is Virbac's FCF Margin % too high?
Virbac's current FCF Margin % of 16.94% is 114% above median its 10-year median of 7.93. Over the past 10 years, this metric has ranged from a low of 3.73 to a high of 11.75. The Drug Manufacturers industry median FCF Margin % is 2.51. Virbac's value of 16.94% is 574.9% above this industry median. Based on the distribution chart, Virbac ranks #370 out of 962 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Virbac has a GF Score™ of 91/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Virbac's FCF Margin % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Virbac ranks #370 out of 962 companies for FCF Margin %. This puts Virbac in the upper half of its industry. The industry median FCF Margin % is 2.51. Virbac's value of 16.94% is 574.9% above this benchmark. Historically, Virbac's own FCF Margin % has ranged from 3.73 to 11.75 over the past decade. While the company's 10-year median is 7.93 vs. the industry median of 2.51, Virbac has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Drug Manufacturers company?
The median FCF Margin % among Drug Manufacturers companies is 2.51, based on 962 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Virbac's current FCF Margin % of 16.94% is 574.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Virbac and its competitors. For the Drug Manufacturers industry, the median FCF Margin % is 2.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Virbac's current FCF Margin % is 16.94%, which is 114% above median its own 10-year median of 7.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Virbac stock overvalued right now?
Based on GuruFocus' analysis, Virbac (LTS:0NM7) is currently considered Modestly Undervalued. The stock's GF Value™ is €364.75, compared to a current price of €322.50 — trading 11.6% below its estimated fair value. The current FCF Margin % is 16.94%, which is 114% above median its 10-year median of 7.93 and 574.9% above the Drug Manufacturers industry median of 2.51. Virbac's overall GF Score™ is 91/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Virbac (LTS:0NM7), the current FCF Margin % is 16.94% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Virbac (LTS:0NM7) Overvalued in 2026?
Based on GuruFocus' analysis, Virbac stock appears to be undervalued.
The current stock price of €322.50 is trading 11.6% below its estimated GF Value™ of €364.75.
GuruFocus considers Virbac to be Modestly Undervalued.
Key valuation signals for LTS:0NM7:
FCF Margin %: 16.94% (114% above median its 10-year median of 7.93)
GF Value™: €364.75 vs. price of €322.50 (11.6% below fair value)
Industry Position: 574.9% above the Drug Manufacturers median (#370 of 962)
No single metric tells the full story. See the LTS:0NM7 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Virbac SA is a drug manufacturing company with a focus on animal health. The company generates the vast majority of its revenue in Europe, and it also has its presence in Europe, North America, Far East Asia, India, Africa & Middle East (IMEA), Pacific, and Latin America.
91GF Score
Get the complete analysis for LTS:0NM7
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0NM7 has been successfully added to your 
